USRE39496E1 - Kahalalide F and compositions and uses thereof - Google Patents
Kahalalide F and compositions and uses thereof Download PDFInfo
- Publication number
- USRE39496E1 USRE39496E1 US10/642,006 US64200603A USRE39496E US RE39496 E1 USRE39496 E1 US RE39496E1 US 64200603 A US64200603 A US 64200603A US RE39496 E USRE39496 E US RE39496E
- Authority
- US
- United States
- Prior art keywords
- val
- compound
- thr
- ileu
- mehex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RCGXNDQKCXNWLO-GZEKAAEYSA-N C/C=C1\NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(NC(=O)C(CCCN)NC(=O)C2CCCN2C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCC(C)C)C(C)C)C(C)O)C(C)C)C(C)C)C(C)CC)C(C)OC(=O)C(C(C)C)NC1=O Chemical compound C/C=C1\NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(NC(=O)C(CCCN)NC(=O)C2CCCN2C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCC(C)C)C(C)C)C(C)O)C(C)C)C(C)C)C(C)CC)C(C)OC(=O)C(C(C)C)NC1=O RCGXNDQKCXNWLO-GZEKAAEYSA-N 0.000 description 4
- CQEMRRJAQVCICJ-XYKADRHJSA-N C.C/C=C1\NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(NC(=O)C(CCCN)NC(=O)C2CCCN2C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCC(C)C)C(C)C)C(C)O)C(C)C)C(C)C)C(C)CC)C(C)OC(=O)C(C(C)C)NC1=O Chemical compound C.C/C=C1\NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(NC(=O)C(CCCN)NC(=O)C2CCCN2C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCC(C)C)C(C)C)C(C)O)C(C)C)C(C)C)C(C)CC)C(C)OC(=O)C(C(C)C)NC1=O CQEMRRJAQVCICJ-XYKADRHJSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N CCOC(C)=O.CO Chemical compound CCOC(C)=O.CO UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention is concerned with a cytotoxic and antiviral compound isolated from the sacoglossan, Elysia rafescens rufescens.
- the present invention also provides a method of treating any mammal affected by a malignant tumor sensitive to compounds above described, which comprises administering to the affected individual a therapeutically effective amount of these compounds or a pharmaceutical composition thereof; and a method of treating viral infections in mammals, comprising administering to a patient in need of such treatment, an antiviral effective amount of the compounds described in the present invention.
- the present invention also relates to pharmaceutical preparations which contain as active ingredient these compounds, or a pharmaceutically acceptable acid addition salt thereof, as well as the process for its preparation.
- compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) suitable composition for oral, topical or parenteral administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. These compositions may need to be sterile when administered parenterally.
- a pharmaceutical composition of these compounds this compound will vary according to the particular formulation, the mode of application and particular site, host and tumor being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of disease shall be taken in account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
- Kahalalide F was isolated from the sacoglossan, Elysia rufescens Elysia rufescens (family Plakobranchidae, order Sacoglossa), collected near Black point Point, Oahu. This animal varies in size between 1 and 4 cm; it is dark red-brown in color with light-colored spots. There is orange fringing of the parapodia, which have very small dark green spots from sequestered chloroplasts. Elysia rufescens feeds on the delicate, feather-like green alga Bryopsis Bryopsis sp. 1 Kahalalide F can also be isolated from this alga.
- Kahalalide F was isolated as a white amorphous powder in 0.02% 0 . 01 % yield.
- a molecular formula of C 75 H 124 N 14 O 16 was deduced from detailed analyses of the 13 C and 1 H NMR spectra and the high resolution FAB mass spectrum.
- the 14 substructures in this compound arise from five valines, two isoleucines, two threonines, ornithine, dehydroaminobutyric acid. , proline, phenilalanine phenylalanine and 5-methythexanoic 5 - methylhexanoic acid (5-MeHex).
- Kahalalide F is the largest peptide in this series of compounds.
- Optical rotations were measured on a Jasco DIP-370 digital polarimeter. Infrared spectra were recorded on a Nicolet MX-5 FTIR spectrometer. Gas chromatography was accomplished using a Hewlett-Packard Model 5890 instrument. Mass spectra were measured on a VG-70SE magnetic sector mass spectrometer. NMR spectra were measured on a General Electric QE-300 or a GN OMEGA 500 instrument. 1 H NMR chemical shifts are reported in ppm with the chemical shift of the residual protons of the solvent used as internal standards. 13 C NMR chemical shifts are reported in ppm by using the natural abundance 13 C of the solvent as an internal standard. Ultraviolet spectra were recorded on a Hewlett-Packard Model 8452A diode array spectrophotometer. All solvents were distilled from glass before use.
- Kahalalide F consists of 2-D-allo-Ileu, L-Orn, L-Phe, D-Pro, L-Thr, D-Allo-Thr, 3 D-Val and 2 L-Val.
Abstract
Description
This invention is concerned with a cytotoxic and antiviral compound isolated from the sacoglossan, Elysia rafescens rufescens.
According to the invention there is provided, a the new compound, the peptide, Kahalalide F, of the formula I:
The antitumor activities of this compound has been determined “in vitro” in cell cultures of human lung carcinoma A-549 and human colon carcinoma HT-29. The procedure was carried out using the metnhodology methodology described by Raymond J. Bergeron et al. Biochem. Bioph. Res. Comm. 1984, 121(3), 848-854 and by Alan C. Schroeder et al. J. Med. Chem. 1981, 24 1078-1083.
The antiviral activities of this compound the compound Kahalalide F have also been determined “in vitro” against HSV (Herpes simplex virus) and VSV (Vesicular stomatitis virus). The methodology used to carry out this determination is described by Raymond J. Bergeron et al. Biochem. Bioph. Res. Comm. 1984, 121(3), 848-854 and by Alan C. Schroeder et al. J. Med. Chem. 1981, 24 1078-1083.
Therefore, the present invention also provides a method of treating any mammal affected by a malignant tumor sensitive to compounds above described, which comprises administering to the affected individual a therapeutically effective amount of these compounds or a pharmaceutical composition thereof; and a method of treating viral infections in mammals, comprising administering to a patient in need of such treatment, an antiviral effective amount of the compounds described in the present invention.
The present invention also relates to pharmaceutical preparations which contain as active ingredient these compounds, or a pharmaceutically acceptable acid addition salt thereof, as well as the process for its preparation.
Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) suitable composition for oral, topical or parenteral administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. These compositions may need to be sterile when administered parenterally.
The correct dosage of a pharmaceutical composition of these compounds this compound will vary according to the particular formulation, the mode of application and particular site, host and tumor being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of disease shall be taken in account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
Kahalalide F was isolated from the sacoglossan, Elysia rufescens Elysia rufescens (family Plakobranchidae, order Sacoglossa), collected near Black point Point, Oahu. This animal varies in size between 1 and 4 cm; it is dark red-brown in color with light-colored spots. There is orange fringing of the parapodia, which have very small dark green spots from sequestered chloroplasts. Elysia rufescens feeds on the delicate, feather-like green alga Bryopsis Bryopsis sp. 1 Kahalalide F can also be isolated from this alga. Two hundred animals were collected over the period of several weeks during the spring, of 1991 and extracted with EtOH. The extracts were then chromatographed by silica gel flash chromatography (hexane, hexane/EtOAc (1:1), EtOAc, EtOAc (1:1) EtOAc/MeOH ( 1:1 ), MeOH and MeOH/HOAc (98:2)). The peptides were eluted with EtOAc/MeOH (1:1). Final purification was accomplished by repeated HPLC (RP C18) using MeCN/H2O with 0.1% TFA (70-45% H2O).
The structures of the peptides were elucidated by 2D NMR experiments (HMQC, HMBC, TOCSY, COSY and ROESY).
Kahalalide F was isolated as a white amorphous powder in 0.02% 0.01% yield. A molecular formula of C75H124N14O16 was deduced from detailed analyses of the 13C and 1H NMR spectra and the high resolution FAB mass spectrum. The 14 substructures in this compound arise from five valines, two isoleucines, two threonines, ornithine, dehydroaminobutyric acid. , proline, phenilalanine phenylalanine and 5-methythexanoic 5-methylhexanoic acid (5-MeHex). Kahalalide F is the largest peptide in this series of compounds.
General Considerations
Optical rotations were measured on a Jasco DIP-370 digital polarimeter. Infrared spectra were recorded on a Nicolet MX-5 FTIR spectrometer. Gas chromatography was accomplished using a Hewlett-Packard Model 5890 instrument. Mass spectra were measured on a VG-70SE magnetic sector mass spectrometer. NMR spectra were measured on a General Electric QE-300 or a GN OMEGA 500 instrument. 1H NMR chemical shifts are reported in ppm with the chemical shift of the residual protons of the solvent used as internal standards. 13C NMR chemical shifts are reported in ppm by using the natural abundance 13C of the solvent as an internal standard. Ultraviolet spectra were recorded on a Hewlett-Packard Model 8452A diode array spectrophotometer. All solvents were distilled from glass before use.
Two hundred sacoglossans (Elysia rufescens), were collected at Black Point, O'ahu during April and May 1992 1991, and extracted 3 times with EtOH. Spring appears to be the time of year Elysia rufescens is in greatest abundance at Black Point. The combined extracts were then chromatographed using silica gel flash chromatography (hexane, hexane/EtOAc (1:1), EtOAc, EtOAc/MeOH (1:1), MeOH, MeOH/HOAc (98:2)). The depsipeptides were found in the EtOAc/MeOH (1:1) fraction. Repeated HPLC RP18 RP C18 MeCN/H2O/TFA (55/45/1 30/70/1)—MeCN/H2O/TFA ((30/70/1 55/45/1) yielded six the new depsipeptides.
KAHALALDDE FKAHALALIDE F
Final purification was accomplished by HPLC on RP18 RP C18 MeCN/H2O/TFA (55/45/1). Physical data: [α]D-8° [α]D- 8° (c 4.32, MeOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz); Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 ( 3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation) d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5-MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m) ; 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 70.40 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172-94 172.94 (1), 58.57 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5), 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7) ; IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1465 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85) (calcd for C75H125N14O16: 1477.9398); UV (MeOH): λmax 204 (89,630) nm.
Amino acid analysis by GC-MS with a Chirasil-Val column indicates that Kahalalide F consists of 2-D-allo-Ileu, L-Orn, L-Phe, D-Pro, L-Thr, D-Allo-Thr, 3 D-Val and 2 L-Val.
TABLE IITABLE I |
1H and 13C NMR Data for Kahalalide F (I)KF in DMF/TFA |
Amino Acid | Carbon | 13C, ppma | Mult. | 1H, ppmb | Multiplicity |
Valine-1 | 1 | 170.4 | s | (NH) 7.11 | d, J=8.9 |
2 | 60.3 | d | 4.16 | t, J=9.0 | |
3 | 30.8 | d | 1.77 | m | |
4 | 19.6 | q | 0.95 | m | |
5 | 18.8 | q | 0.95 | m | |
Dehydroamino | 1 | 164.5 | s | (NH) 9.20 | s |
butyric acid | 2 | 130.3 | s | ||
3 | 131.3 | d | 6.48 | q, J=6.9 | |
4 | 12.7 | q | 1.43 | d, J=6.6 | |
Phenylalanine | 1 | 171.3 | s | (NH) 8.62 | d, J=6.6 |
2 | 56.3 | d | 4.68 | q, J=6.6 | |
3 | 36.8 | t | 3.23 | dd, J=13.7, | |
3.00 | 7.2 | ||||
3.00 | dd, J=13.7, | ||||
9.0 | |||||
4 | 138.2 | s | |||
5, 5′ | 129.9 | d | 7.32 | d, J=7.2 | |
6, 6′ | 128.8 | d | 7.28 | t, J=7.5 | |
7 | 127.0 | d | 7.21 | t, J=7.2 | |
Valine-2 | 1 | 172.9 | s | (NH) 7.82 | d, J=6.6 |
2 | 58.6 | d | 4.36 | m | |
3 | 32.4 | d | 2.12 | m | |
4 | 18.0 | q | 0.85 | m | |
5 | 17.6 | q | 0.77 | d, J=6.6 | |
Isoleucine-1 | 1 | 171.9 | s | (NH) 8.38 | d, J=0.6 |
2 | 57.5 | d | 4.53 | m | |
3 | 38.8 | d | 1.98 | m | |
4 | 14.6 | q | 0.92 | d, J=6.6 | |
5 | 26.8 | t | 1.40, 1.13 | m, m | |
6 | 11.7 | q | 0.88 | t, J=7.2 | |
Threonine-1 | 1 | 169.7 | s | (NH) 8.12 | d, J=5.7 |
2 | 57.4 | d | 4.63 | t, J=9.3 | |
3 | 71.1 | d | 5.07 | dq, J=9.6, 6.0 | |
4 | 17.3 | q | 1.18 | d, J=6.3 | |
Isoleucine-2 | 1 | 171.9 | s | (NH) 7.72 | d, J=8.4 |
2 | 57.3 | d | 4.52 | m | |
3 | 38.0 | d | 1.88 | m | |
4 | 14.8 | q | 0.88 | d, J=6.3 | |
5 | 26.6 | t | 1.40, 1.13 | m, m | |
6 | 11.6 | q | 0.88 | t, J=7.2 | |
Ornithine | 1 | 172.0 | s | (NH) 7.92 | d, J=7.8 |
2 | 52.9 | d | 4.48 | m | |
3 | 29.6 | t | 1.76 | m | |
4 | 24.4 | t | 1.83 | m | |
5 | 40.1 | t | 3.10 | p, 5.1 | |
Proline | 1 | 172.6 | s | ||
2 | 60.2 | d | 4.42 | m | |
3 | 29.6 | t | 2.12, 1.97 | m, m | |
4 | 25.4 | t | 2.02, 1.88 | m, m | |
5 | 48.0 | t | 3.75, 3.68 | m, m | |
Valine-3 | 1 | 171.3 | s | (NH) 7.90 | d, J=7.2 |
2 | 57.6 | d | 4.41 | m | |
3 | 30.5 | d | 2.12 | m | |
4 | 19.6 | q | 0.95 | m | |
5 | 18.8 | q | 0.85 | m | |
Valine-4 | 1 | 171.8 | s | (NH) 7.68 | d, J=8.1 |
2 | 59.1 | d | 4.34 | m | |
3 | 31.3 | d | 2.17 | m | |
4 | 19.5 | q | 0.95 | m | |
5 | 18.1 | q | 0.90 | m | |
Threonine-2 | 1 | 171.0 | s | (NH) 7.77 | d, J=8.1 |
2 | 58.9 | d | 4.46 | m | |
3 | 67.4 | d | 4.21 | dq, J=6.3, 3.6 | |
4 | 19.7 | q | 1.12 | d, J=6.6 | |
Valine-5 | 1 | 172.7 | s | (NH) 7.85 | d, J=8.1 |
conf. #2 | 7.85 | d, J=7.81 | |||
(NH) 7.82 | |||||
2 | 59.6 | d | 4.32 | m | |
3 | 30.7 | d | 2.14 | m | |
4 | 19.6 | q | 0.95 | m | |
5 | 18.4 | q | 0.90 | m | |
5-Methyl- | 1 | 173.8 | s | ||
Hexanoic acid | 2 | 36.3 | t | 2.26 | m |
3 | 24.0 | t | 1.60 | m | |
4 | 39.0 | t | 1.20 | m | |
5 | 28.1 | d | 1.55 | m | |
6 | 22.5 | q | 0.87 | d, J=7.2 | |
7 | 22.5 | q | 0.87 | d, J=7.2 | |
5-Methyl- | 1 | 174.1 | s | ||
Hexanoic acid | 2 | 33.9 | t | 2.29 | m |
(second | 3 | 32.8 | t | 1.65, 1.40 | m |
conformation) | 4 | 29.8 | t | 1.13 | m |
5 | 34.5 | d | 1.35 | m | |
6 | 19.5 | q | 0.90 | m | |
7 | 11.2 | q | 0.90 | m | |
aat 125 MHz, DMF signal at 35.2 ppm; | |||||
bat 500 MHz, DMF signal at 2.91 ppm. |
TABLE ITABLE II |
In vitro Activity of Kahalalide F KF from Elysia rufescens |
Assay (M.I.C. μg/mL) |
Cytoxicity μg/mL (IC50) |
A-549 | 2.5 | |
HT-29 | 0.25-0.5 |
Antiviral μg/mL (% reduction) |
Mv 2 Lu/HSV II | 0.5 (95%) | ||
CV-1/HSV-1 | >8 | ||
BHK/VSV | >8 | ||
Antifungal 6 mm disk | 50 μg/disk | ||
Aspergillus oryzae | 19 mm | ||
Penicillium notatum | 26 mm | ||
Tricophyton mentagrophy | 34 mm | ||
Saccharomyces cerevisiac | neg | ||
Candida albicans | 16 mm | ||
Claims (10)
1. A substially Substantially pure compound Kahalalide F compound, said compound hag having a molecular formula of C75H124N14O16, and consisting of five valines, two isoleucines, two threonines, ornithine, dehydroaminobutynic dehydroaminobutyric acid, proline, phenylalanine and 5-methylhexanoic acid; said compound further exhibiting the following physical and chemical properties: [α]D-8° (c 4.32, MeOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, m), Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Vol-2 Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (HN NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1 Hz), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85 (HN NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5-MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=72 7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 126.6 12.68 (4); Phe 171.31 (1), 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.57 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4) 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); thr-2 Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
3. A pharmaceutical compostion composition comprising a pharmaceutical carrier or diluent and the substantially pure compound Kahalalide F, said compoumd compound having a molecular formula of C75H124N14O16, and conng consisting of five valines, two isoleucines, two threonines, ornithine, dehydroamiobutyric dehydroaminobutyric acid, proline, phenylalanine and 5-methylhexoic 5-methylhexanoic acid; said compound further exhibiting the following physical and chemical properties:
[α]D-8° (c 4.32, MEOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, ma m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 Ileu- 1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1Hz), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56-27 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.27 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.35 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
5. A method of treating fungal infections in mammals comprising administering to a patient in need of such treatment, an amount of the substantially puxe compound pure Kahalalide F compound or a pharmaceutically acceptable salt thereof, sufficient to slow or stop the growth of the fungal infection; said compound having a molecula molecular formula of C75H124N14O16, and consisting of five valines, two isoleucines, two theonines threonines, ornithine, dehydroaminobutiric dehydroaminobutyric acid, proline, phenylalanie phenylalanine and 5-methylhexanoic acid; said compound further exhibiting the folowing following physical and chemical properties:
[α]D-8° (c 4.32, MEOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, ma m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ilue-1 Ileu- 1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m) 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz, TFA/DMF): amino acid unit, 6 (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56-27 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.27 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.35 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
7. The method of claim 5 , wherein the fungal infection is caused by Aspergillus oryzae.
8. The method of claim 5 , wherein the fungal infection is caused by Penicillium notatum.
9. The method of claim 5 , wherein the fungal infection is caused by Trichophyton mentagrophy.
10. The method of claim 5 , wherein the fungal infection is caused by Candida albicans.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/642,006 USRE39496E1 (en) | 1993-02-03 | 2003-08-14 | Kahalalide F and compositions and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939302046A GB9302046D0 (en) | 1993-02-03 | 1993-02-03 | Antiumoral compound-v |
US08/192,569 US6274551B1 (en) | 1994-02-03 | 1994-02-03 | Cytotoxic and antiviral compound |
US10/642,006 USRE39496E1 (en) | 1993-02-03 | 2003-08-14 | Kahalalide F and compositions and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/192,569 Reissue US6274551B1 (en) | 1993-02-03 | 1994-02-03 | Cytotoxic and antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39496E1 true USRE39496E1 (en) | 2007-02-27 |
Family
ID=22710214
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/192,569 Ceased US6274551B1 (en) | 1993-02-03 | 1994-02-03 | Cytotoxic and antiviral compound |
US08/935,073 Expired - Lifetime US6011010A (en) | 1994-02-03 | 1997-09-25 | Cytotoxic and antiviral compound |
US10/642,006 Expired - Lifetime USRE39496E1 (en) | 1993-02-03 | 2003-08-14 | Kahalalide F and compositions and uses thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/192,569 Ceased US6274551B1 (en) | 1993-02-03 | 1994-02-03 | Cytotoxic and antiviral compound |
US08/935,073 Expired - Lifetime US6011010A (en) | 1994-02-03 | 1997-09-25 | Cytotoxic and antiviral compound |
Country Status (1)
Country | Link |
---|---|
US (3) | US6274551B1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214755A1 (en) * | 2000-02-09 | 2004-10-28 | Fernando Albericio | Kahalalide f and related compounds |
US20070117743A1 (en) * | 2003-09-09 | 2007-05-24 | Palomera Fernando A | New antitumoral compounds |
US20080090757A1 (en) * | 2003-02-26 | 2008-04-17 | Pharma Mar, S.A.U. | Kahalalide Compositions for the Treatment of Psoriasis |
US7683028B2 (en) | 2003-02-26 | 2010-03-23 | Pharma Mar, S.A.U. | Kahalalide compositions |
US20100226919A1 (en) * | 2007-10-19 | 2010-09-09 | Pharma Mar, S.A. | Antitumoral Treatments |
US20100323021A1 (en) * | 2008-01-30 | 2010-12-23 | Pharma Mar, S.A. | Antitumoral treatments |
US20110015135A1 (en) * | 2008-03-07 | 2011-01-20 | Pharma Mar S.A. | Antitumoral Treatments |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568192A (en) * | 2000-10-31 | 2005-01-19 | 法马马有限公司 | Kahalalide F formulation |
US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
EP1572726B1 (en) * | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
US20040242886A1 (en) * | 2003-04-30 | 2004-12-02 | Sandeep Gupta | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications |
US20040248877A1 (en) * | 2003-04-30 | 2004-12-09 | Sandeep Gupta | Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof |
US7457885B2 (en) * | 2005-02-10 | 2008-11-25 | Asoka Usa Corporation | Powerline communication system and method using coupler design for additional users |
GB0408958D0 (en) * | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
WO2007100385A2 (en) * | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035613A2 (en) * | 2002-10-18 | 2004-04-29 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalaide f compound |
US20040214755A1 (en) * | 2000-02-09 | 2004-10-28 | Fernando Albericio | Kahalalide f and related compounds |
-
1994
- 1994-02-03 US US08/192,569 patent/US6274551B1/en not_active Ceased
-
1997
- 1997-09-25 US US08/935,073 patent/US6011010A/en not_active Expired - Lifetime
-
2003
- 2003-08-14 US US10/642,006 patent/USRE39496E1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214755A1 (en) * | 2000-02-09 | 2004-10-28 | Fernando Albericio | Kahalalide f and related compounds |
WO2004035613A2 (en) * | 2002-10-18 | 2004-04-29 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalaide f compound |
Non-Patent Citations (5)
Title |
---|
Goetz et al, Tetrahedron, 55 (1999), pp. 7729-7746. * |
Hamann et al, J. Org. Chem. (1996), 61, 6594-6600. * |
Hamann et al., J. Am. Chem. Soc., 115, pp. 5825-5826, Jul. 1, 1993. |
Merch Manual, 11<SUP>th </SUP>ed., pp. 456-459, 761-763, and 1368-1371; published 1969. |
UMI Dissertation Services, "Biologically Active Constituents of Some Marine Invertebrates," Hamann, Mark Todd, Ph.D., University of Hawaii (1992), published Oct. 1993. |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214755A1 (en) * | 2000-02-09 | 2004-10-28 | Fernando Albericio | Kahalalide f and related compounds |
US7482429B2 (en) * | 2000-02-09 | 2009-01-27 | Pharma Mar, S.A. | Kahalalide F and related compounds |
US20080090757A1 (en) * | 2003-02-26 | 2008-04-17 | Pharma Mar, S.A.U. | Kahalalide Compositions for the Treatment of Psoriasis |
US7683028B2 (en) | 2003-02-26 | 2010-03-23 | Pharma Mar, S.A.U. | Kahalalide compositions |
US20070117743A1 (en) * | 2003-09-09 | 2007-05-24 | Palomera Fernando A | New antitumoral compounds |
US20100226919A1 (en) * | 2007-10-19 | 2010-09-09 | Pharma Mar, S.A. | Antitumoral Treatments |
US20100323021A1 (en) * | 2008-01-30 | 2010-12-23 | Pharma Mar, S.A. | Antitumoral treatments |
US20110015135A1 (en) * | 2008-03-07 | 2011-01-20 | Pharma Mar S.A. | Antitumoral Treatments |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
US11332480B2 (en) | 2017-04-27 | 2022-05-17 | Pharma Mar, S.A. | Antitumoral compounds |
US11339180B2 (en) | 2017-04-27 | 2022-05-24 | Pharma Mar, S.A. | Antitumoral compounds |
US11713325B2 (en) | 2017-04-27 | 2023-08-01 | Pharma Mar, S.A. | Antitumoral compounds |
Also Published As
Publication number | Publication date |
---|---|
US6011010A (en) | 2000-01-04 |
US6274551B1 (en) | 2001-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE39496E1 (en) | Kahalalide F and compositions and uses thereof | |
EP0679092B1 (en) | Cytokine restraining agents | |
DE3100974C2 (en) | ||
JP2919965B2 (en) | Dehydrodidemnin B | |
CA1270596A (en) | Peptide derivatives having a nitrogenous polycyclic structure and process for their preparation | |
US4024248A (en) | Peptides having LH-RH/FSH-RH activity | |
EP1378522A2 (en) | Methods of enhancing bioactivity of chemokines | |
EP0610078B1 (en) | Cytotoxic and antiviral compound | |
US8435939B2 (en) | Polypeptide anti-HIV agent containing the same | |
JP3178835B2 (en) | Novel polypeptide and anti-HIV agent using the same | |
HUT73674A (en) | Biologically active vasopressin analogues | |
EP1309613B1 (en) | Pharmaceutical composition comprising an analgesic peptide | |
EP0380623B1 (en) | Irreversible peptide ligands for bombesin receptors | |
EP0378432B1 (en) | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | |
RU2536588C2 (en) | New bacitracin antibiotics | |
CA1062250A (en) | Tripeptide derivatives with central nervous system activity and preparation thereof | |
RU1124544C (en) | Heptapeptide possessing properties of psychostimulator of prolonged action with immunotropic activity | |
IE903958A1 (en) | Reduced irreversible bombesin antagonists | |
JPH0672152B2 (en) | Thymosin α1-fragment and immunomodulator containing the compound | |
US3948876A (en) | Process for the purification of synthetic calcitonins | |
WO1997039025A1 (en) | A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp. | |
EP0919567B1 (en) | Novel peptides and nootropic agent | |
AU678329C (en) | Cytokine restraining agents | |
HUT70179A (en) | Process for producing retroinverted tetrapeptides and pharmaceutical compositions containing them as active component | |
CA2128552A1 (en) | Derivatives of 6,7-dihydroxy-4-thiaheptanoic acid and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |